Identifying resistance to cancer immunotherapy using advanced imaging techniques
Early identification of immunotherapy resistance through integrated multiparameter imaging
This study is looking at new ways to see if cancer patients are not responding to their immunotherapy treatments, so doctors can adjust their care to keep them safe and healthy while getting the best results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11050284 on NIH RePORTER |
What this research studies
This research focuses on developing non-invasive imaging methods to detect when cancer patients are not responding to immunotherapy treatments. By understanding the mechanisms behind resistance, the study aims to help doctors keep patients on effective therapies while avoiding harmful side effects from other treatments. The approach involves monitoring specific immune responses and tumor characteristics to tailor treatment strategies for better outcomes. Patients who are receiving immune checkpoint inhibitors for cancer will be the primary focus of this investigation.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients currently undergoing immunotherapy, particularly those receiving immune checkpoint inhibitors.
Not a fit: Patients who are not receiving immunotherapy or those with cancers not targeted by immune checkpoint inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for cancer patients, allowing for better management of immunotherapy and enhanced patient outcomes.
How similar studies have performed: Other research has shown promise in using imaging techniques to monitor treatment responses in cancer, suggesting that this approach could be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Anwar, Mekhail — University of California, San Francisco
- Study coordinator: Anwar, Mekhail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.